glp 1 agonist black box warning Liraglutide, the first long acting GLP-1RA was approved 12 years ago with a for MTC based on rodent data. After millions of Rx, registry and real world data show Did You Know? GLP-1 Receptor

In contrast to the case reports on altered renal function seen with exenatide, a pooled analysis of 5,594 participants from 19 randomized, controlled clinical trials of exenatide twice-daily (5 g and 10 g) showed that renal impairment-related adverse events, including acute renal failure, were rare (1.6 per 100 person-years for both groups)

Ruas JS, Siqueira-Santos ES, Amigo I, Rodrigues-Silva E, Kowaltowski AJ, Castilho RF

SGLT2-i lower SBP by an average of ~2.5-4.0 mmHg and DBP by 1.5-2.0 mmHg

Native GLP-1 and Gastric Emptying Acute IV administration of GLP- 1 slows gastric emptying profoundly and dose-dependently (12), accompanied by relaxation of the gastric fundus, increased gastric compliance, inhibition of antral contractility, and increased pyloric tone (13, 14)

As research continues to uncover its mechanisms and optimize its therapeutic application, allulose may emerge as a valuable tool in the management of metabolic disorders

Krishnamurthy Clinical Research Coordinator, South Asia A clearly defined documentation pathway and upfront compliance screening supported a structured and transparent internal approval process. R